Tokyo Tape
Sign in
← Ain Holdings

Quarterly report · Q2

9627.TEDINET S100SH2U
Period2023-05-01 → 2023-10-31
Filed2023-12-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥193.7bn2023-05-01 → 2023-10-31Cons.Net sales
Revenue¥358.7bn2022-05-01 → 2023-04-30Cons.Net sales (5-year summary)
Revenue¥171.2bn2022-05-01 → 2022-10-31Cons.Net sales
Operating income¥8.7bn2023-05-01 → 2023-10-31Cons.Operating income
Operating income¥6.8bn2022-05-01 → 2022-10-31Cons.Operating income
Ordinary income¥9.3bn2023-05-01 → 2023-10-31Cons.Ordinary income
Ordinary income¥17.1bn2022-05-01 → 2023-04-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.3bn2022-05-01 → 2022-10-31Cons.Ordinary income
Profit before tax¥9.4bn2023-05-01 → 2023-10-31Cons.Income before income taxes
Profit before tax¥7.2bn2022-05-01 → 2022-10-31Cons.Income before income taxes
Net income (owners)¥5.3bn2023-05-01 → 2023-10-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥9.2bn2022-05-01 → 2023-04-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.8bn2022-05-01 → 2022-10-31Cons.Profit loss attributable to owners of parent
Net income¥5.2bn2023-05-01 → 2023-10-31Cons.Profit loss
Net income¥3.8bn2022-05-01 → 2022-10-31Cons.Profit loss
Total assets¥242.9bnat 2023-10-31Cons.Assets
Total assets¥231.8bnat 2023-04-30Cons.Assets
Total assets¥231.3bnat 2022-10-31Cons.Total assets (5-year summary)
Total liabilities¥113.1bnat 2023-10-31Cons.Liabilities
Total liabilities¥105.2bnat 2023-04-30Cons.Liabilities
Net assets / equity¥129.8bnat 2023-10-31Cons.Net assets
Net assets / equity¥126.5bnat 2023-04-30Cons.Net assets
Net assets / equity¥120.9bnat 2022-10-31Cons.Net assets (5-year summary)
Cash and deposits¥50.5bnat 2023-10-31Cons.Cash and deposits
Cash and deposits¥46.8bnat 2023-04-30Cons.Cash and deposits
Cash & equivalents¥50.3bnat 2023-10-31Cons.Cash and cash equivalents
Cash & equivalents¥46.2bnat 2023-04-30Cons.Cash and cash equivalents
Cash & equivalents¥43.5bnat 2022-10-31Cons.Cash and cash equivalents
Cash & equivalents¥59.5bnat 2022-04-30dCons.Cash and cash equivalents
Operating cash flow¥14.1bn2023-05-01 → 2023-10-31Cons.Net cash provided by used in operating activities
Operating cash flow¥20.3bn2022-05-01 → 2023-04-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥8.5bn2022-05-01 → 2022-10-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥5.8bn2023-05-01 → 2023-10-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥22.3bn2022-05-01 → 2023-04-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18.6bn2022-05-01 → 2022-10-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥4.2bn2023-05-01 → 2023-10-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥11.2bn2022-05-01 → 2023-04-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.8bn2022-05-01 → 2022-10-31Cons.Net cash provided by used in financing activities
EPS (basic)¥149.662023-05-01 → 2023-10-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥88.732023-08-01 → 2023-10-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥262.872022-05-01 → 2023-04-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥108.322022-05-01 → 2022-10-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.782022-08-01 → 2022-10-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio53.4%at 2023-10-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.6%at 2023-04-30Cons.Equity to asset ratio (5-year summary)
Equity ratio52.2%at 2022-10-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Otherother segmentsrevenue2023-05-01 → 2023-10-31¥5.7bn
Otherother segmentsrevenue external2023-05-01 → 2023-10-31¥5.7bn
Otherother segmentsrevenue intersegment2023-05-01 → 2023-10-31¥24m
Otherother segmentssegment ordinary income2023-05-01 → 2023-10-31−¥49m
Reconciling Itemsreconcilingrevenue2023-05-01 → 2023-10-31−¥24m
Reconciling Itemsreconcilingrevenue intersegment2023-05-01 → 2023-10-31−¥24m
Reconciling Itemsreconcilingsegment ordinary income2023-05-01 → 2023-10-31−¥4.4bn
jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segmentrevenue2023-05-01 → 2023-10-31¥173.2bn
jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segmentrevenue external2023-05-01 → 2023-10-31¥173.2bn
jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segmentsegment ordinary income2023-05-01 → 2023-10-31¥12.5bn
jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segmentrevenue2023-05-01 → 2023-10-31¥14.8bn
jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segmentrevenue external2023-05-01 → 2023-10-31¥14.8bn
jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segmentsegment ordinary income2023-05-01 → 2023-10-31¥1.3bn
—segment totalrevenue2023-05-01 → 2023-10-31¥193.8bn
—segment totalrevenue external2023-05-01 → 2023-10-31¥193.7bn
—segment totalrevenue intersegment2023-05-01 → 2023-10-31¥24m
—segment totalsegment ordinary income2023-05-01 → 2023-10-31¥13.8bn
Otherother segmentsrevenue2022-05-01 → 2022-10-31¥5.8bn
Otherother segmentsrevenue external2022-05-01 → 2022-10-31¥5.8bn
Otherother segmentsrevenue intersegment2022-05-01 → 2022-10-31¥31m
Otherother segmentssegment ordinary income2022-05-01 → 2022-10-31−¥18m
Reconciling Itemsreconcilingrevenue2022-05-01 → 2022-10-31−¥31m
Reconciling Itemsreconcilingrevenue intersegment2022-05-01 → 2022-10-31−¥31m
Reconciling Itemsreconcilingsegment ordinary income2022-05-01 → 2022-10-31−¥3.8bn
jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segmentrevenue2022-05-01 → 2022-10-31¥153.2bn
jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segmentrevenue external2022-05-01 → 2022-10-31¥153.2bn
jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segmentsegment ordinary income2022-05-01 → 2022-10-31¥10.8bn
jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segmentrevenue2022-05-01 → 2022-10-31¥12.2bn
jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segmentrevenue external2022-05-01 → 2022-10-31¥12.2bn
jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segmentsegment ordinary income2022-05-01 → 2022-10-31¥349m
—segment totalrevenue2022-05-01 → 2022-10-31¥171.2bn
—segment totalrevenue external2022-05-01 → 2022-10-31¥171.2bn
—segment totalrevenue intersegment2022-05-01 → 2022-10-31¥31m
—segment totalsegment ordinary income2022-05-01 → 2022-10-31¥11.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 555
ItemContextValueUnit
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration171204000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_OtherReportableSegmentsMember31000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember31000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-31000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember153248000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember12205000000JPY
Net salesPrior1YTDDuration_OtherReportableSegmentsMember5781000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember171235000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-31000000JPY
Net salesPrior1YTDDuration171204000000JPY
Ordinary incomePrior1YTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember10771000000JPY
Ordinary incomePrior1YTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember349000000JPY
Ordinary incomePrior1YTDDuration_OtherReportableSegmentsMember-18000000JPY
Ordinary incomePrior1YTDDuration_ReportableSegmentsMember11101000000JPY
Ordinary incomePrior1YTDDuration_ReconcilingItemsMember-3816000000JPY
Ordinary incomePrior1YTDDuration7285000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember173234000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember14832000000JPY
Revenues from external customersCurrentYTDDuration_OtherReportableSegmentsMember5660000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember193727000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration193727000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_OtherReportableSegmentsMember24000000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember24000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-24000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember173234000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember14832000000JPY
Net salesCurrentYTDDuration_OtherReportableSegmentsMember5685000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember193752000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-24000000JPY
Net salesCurrentYTDDuration193727000000JPY
Ordinary incomeCurrentYTDDuration_jpcrp040300-q2r_E04896-000DispensingPharmacyReportableSegmentsMember12492000000JPY
Ordinary incomeCurrentYTDDuration_jpcrp040300-q2r_E04896-000DrugAndCosmeticStoreReportableSegmentsMember1318000000JPY
Ordinary incomeCurrentYTDDuration_OtherReportableSegmentsMember-49000000JPY
Ordinary incomeCurrentYTDDuration_ReportableSegmentsMember13761000000JPY
Ordinary incomeCurrentYTDDuration_ReconcilingItemsMember-4422000000JPY
Ordinary incomeCurrentYTDDuration9338000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-12-15
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第55期第２四半期（自　2023年８月１日　至　2023年10月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社アインホールディングス

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-04-30pass
balance sheet identityconsolidated 2023-10-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-04-30pass
statement vs summary · net assetsconsolidated 2023-10-31pass
statement vs summary · net income attributable to parentconsolidated 2022-05-01/2022-10-31pass
statement vs summary · net income attributable to parentconsolidated 2023-05-01/2023-10-31pass
statement vs summary · operating cash flowconsolidated 2022-05-01/2022-10-31pass
statement vs summary · operating cash flowconsolidated 2023-05-01/2023-10-31pass
statement vs summary · revenueconsolidated 2022-05-01/2022-10-31pass
statement vs summary · revenueconsolidated 2023-05-01/2023-10-31pass
statement vs summary · total assetsconsolidated 2023-04-30pass
statement vs summary · total assetsconsolidated 2023-10-31pass